Lazard Asset Management LLC Purchases 737,536 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Lazard Asset Management LLC raised its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 81.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,641,817 shares of the company's stock after buying an additional 737,536 shares during the period. Lazard Asset Management LLC owned about 3.54% of Omnicell worth $73,093,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in OMCL. Smartleaf Asset Management LLC boosted its holdings in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after purchasing an additional 273 shares in the last quarter. Johnson Financial Group Inc. acquired a new stake in shares of Omnicell in the 4th quarter valued at $37,000. Van ECK Associates Corp boosted its holdings in shares of Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after purchasing an additional 315 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Omnicell in the 4th quarter valued at $53,000. Finally, First Horizon Advisors Inc. lifted its stake in shares of Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after acquiring an additional 355 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.

Omnicell Stock Performance

Omnicell stock traded down $0.12 during mid-day trading on Friday, reaching $27.96. The company's stock had a trading volume of 661,695 shares, compared to its average volume of 559,392. The firm's fifty day moving average price is $31.41 and its two-hundred day moving average price is $39.40. The company has a market capitalization of $1.31 billion, a P/E ratio of 103.56, a PEG ratio of 7.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.10. The company had revenue of $269.67 million during the quarter, compared to analyst estimates of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The firm's quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.03 earnings per share. Sell-side analysts predict that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on OMCL. Benchmark lowered their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. StockNews.com downgraded Omnicell from a "buy" rating to a "hold" rating in a research note on Saturday, May 3rd. JPMorgan Chase & Co. lowered their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, March 20th. Finally, Wells Fargo & Company raised shares of Omnicell from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $31.00 to $35.00 in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $46.50.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.